GITR Antibodies in Cancer: Not Ready for Prime Time.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35834593.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1489.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glucocorticoid-induced TNF receptor (TNFR)-related protein (GITR) agonistic antibodies are expected to increase the antitumor response mainly by reducing the effect of Foxp3+ T-regulatory cells. TRX-518 is a novel GITR agonist that has shown good pharmacodynamic activity by depleting regulatory T cells (Tregs) in preclinical models, with limited clinical activity demonstrated in patients with advanced solid tumors. See related article by Davar et al., p. 3990.
Medical subject headings
- Neoplasms
- Nivolumab